Wordt geladen...
A Phase II Study of RO4929097 Gamma-Secretase Inhibitor in Metastatic Melanoma: SWOG 0933
BACKGROUND: Aberrant Notch activation confers a proliferative advantage onto many human tumors, including melanoma. This phase II trial assessed the antitumor activity of RO4929097, a gamma-secretase inhibitor of Notch signaling, on the progression-free and overall survival of patients with advanced...
Bewaard in:
| Gepubliceerd in: | Cancer |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2014
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4304973/ https://ncbi.nlm.nih.gov/pubmed/25250858 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29055 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|